Log in

View Full Version : General Cancer News

Pages : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 [42] 43 44 45 46 47 48 49 50 51 52 53 54 55
  1. Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast (0 replies)
  2. Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting (0 replies)
  3. News segment highlights value of hyperthermia for treatment of breast cancer (0 replies)
  4. AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium (0 replies)
  5. Lexus of Tacoma donates $3,000 to Carol Milgard Breast Center (0 replies)
  6. New radiation-free device to detect breast cancer (0 replies)
  7. Study finds anastrozole long-term benefits to stop breast cancer (0 replies)
  8. CTRC-AACR Symposium to discuss new findings from breast cancer clinical trial (0 replies)
  9. Study identifies new genes for early menarche (0 replies)
  10. Bare breasts campaign for breast cancer (0 replies)
  11. Breast cancer breakthrough (0 replies)
  12. Dec. 1 news from RSNA 2010 (0 replies)
  13. Regis Corporation raises $1 million for breast cancer research (0 replies)
  14. British Journal: Obesity, alcohol consumption may increase cancer risk (0 replies)
  15. Debiopharm recognised with European Biopharmaceuticals company of the year award (0 replies)
  16. Precision Therapeutics to present abstracts on breast cancer therapy at San Antonio S (0 replies)
  17. Men with long index fingers at lower risk of prostate cancer (0 replies)
  18. Study shows link between reduced hormone therapy and decline in breast cancer (0 replies)
  19. Annual mammography screening reduces risk of mastectomy (0 replies)
  20. Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting (0 replies)
  21. University Hospitals receives $42 million for cancer care (0 replies)
  22. Genetic screening for Lynch syndrome as cost-effective as other cancer screening proc (0 replies)
  23. U-Systems upgrades ABUS system to improve diagnostic efficiency, quality (0 replies)
  24. New findings suggest targeting DNA in later-stage could be effective to treat breast (0 replies)
  25. Positive results from Oncolytics' combination REOLYSIN-docetaxel Phase I trial in adv (0 replies)
  26. Baylor Health Care System receives $20 million to benefit transplantation initiatives (0 replies)
  27. Texas Breast Specialists expands breast cancer treatment services (0 replies)
  28. ACS recommends annual MRI screening in women with family history of breast cancer (0 replies)
  29. GE Healthcare to highlight technologies to support healthymagination strategy at RSNA (0 replies)
  30. IMPAX for breast imaging eliminates limitations of modality-specific review stations (0 replies)
  31. Personalized oncology requires new paradigm for drug development, experts say (0 replies)
  32. Researchers explain molecular mechanism that induces HER2+ tumours to ignore cell sig (0 replies)
  33. LCA calls for public discussion on guidance for lung cancer screening (0 replies)
  34. Cancers detected late leading to unnecessary deaths: Report (0 replies)
  35. Does anybody know where I can find a good iseries web site with technical data? (0 replies)
  36. A new treatment landscape for triple-negative breast cancer (0 replies)
  37. Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer ce (0 replies)
  38. Provectus reports progress in PV-10 program for metastatic melanoma (0 replies)
  39. IDSI submits Premarket Notification for CTLM breast imaging device to FDA (0 replies)
  40. Disrupting estrogen pathway can halt expansion of breast cancer stem cells: Research (0 replies)
  41. Hologic announces receipt of FDA approvable letter for Selenia Dimensions 3-D digital (0 replies)
  42. DiaGenic ASA announces subsequent offering of 60,000,000 shares (0 replies)
  43. S*BIO's SB1317 enters Phase 1 clinical trial in patients with advanced/refractory hem (0 replies)
  44. IsoRay to sell $2.25 million in common stock (0 replies)
  45. Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AM (0 replies)
  46. New I-SPY 2 study to evaluate effectiveness of medical treatment for breast cancer (0 replies)
  47. Xgeva receives FDA approval for prevention of SREs in patients with bone metastases (0 replies)
  48. AVEO's RON antibody shows anti-tumor activity in human cancer xenografts (0 replies)
  49. ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR S (0 replies)
  50. Cough suppressant syrup can probe patients' metabolism on tamoxifen for breast cancer (0 replies)
  51. Mouse study finds blocking GnT-V enzyme delays growth of breast cancer (0 replies)
  52. AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointe (0 replies)
  53. Volpara breast imaging software receives FDA clearance (0 replies)
  54. Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium (0 replies)
  55. COPD both a burden and a loss (0 replies)
  56. Multidisciplinary clinic approach can improve survival in patients with aggressive pr (0 replies)
  57. DiaGenic receives 92,738,974 shares in subsequent offering (0 replies)
  58. New technique to identify cancer biomarkers (0 replies)
  59. MK-4827 drug candidate shows promising anti-tumour activity in first human trial (0 replies)
  60. Exelixis reports interim data of XL184 for metastatic castration-resistant prostate c (0 replies)
  61. Scientists develop new method for detecting functional sites on proteins (0 replies)
  62. Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer (0 replies)
  63. U-Systems initiates EASY study for screening breast cancer (0 replies)
  64. Cancer patients can still access NICE rejected drugs (0 replies)
  65. Risk of radiation-induced breast cancer from mammographic screening slight in compari (0 replies)
  66. Targeted therapies could treat broad range of cancers: Research (0 replies)
  67. New OncoMap technique can detect point mutation in ovarian cancer (0 replies)
  68. Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Sympo (0 replies)
  69. Scientists find inhibiting EGFR may help treat triple negative breast cancer (0 replies)
  70. AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capeci (0 replies)
  71. Verastem closes $16 million Series A financing (0 replies)
  72. Merrion prepares Phase III study for Orazol in breast cancer treatment (0 replies)
  73. Leona Aglukkaq announces new research on childhood obesity in Canada (0 replies)
  74. FDA approves Halaven therapy for metastatic late-stage breast cancer (0 replies)
  75. RBC boosting drugs may undermine breast cancer treatment with Herceptin (0 replies)
  76. First Edition: November 15, 2010 (0 replies)
  77. New AccuDetect software reduces false-positive rates during mammography screening (0 replies)
  78. New study finds PEM reduces unnecessary breast biopsies (0 replies)
  79. DS Waters extends partnership with Komen for Cure (0 replies)
  80. SU2C to receive second CLIO Healthcare Award (0 replies)
  81. 33rd CTRC-AACR Symposium to feature breast cancer research (0 replies)
  82. NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research consort (0 replies)
  83. Women and cancer today (0 replies)
  84. Novel mechanism regulating circadian rhythm identified (0 replies)
  85. German Genetic Diagnostics Act in need of amendment (0 replies)
  86. Marker for aggressive form of idiopathic pulmonary fibrosis discovered (0 replies)
  87. AACR forum to focus on new advancements in cancer management among women (0 replies)
  88. Cyclacel announces publication of sapacitabine to reduce tumor growth in British Jour (0 replies)
  89. Alnylam presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Sym (0 replies)
  90. Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine devel (0 replies)
  91. Epimutation in BRCA1 gene may cause early-onset of breast cancer (0 replies)
  92. Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC (0 replies)
  93. Medicinal mushroom formula fights breast cancer (0 replies)
  94. COPD awareness is increasing among Americans (0 replies)
  95. Breast cancer patients more likely to have joint pain from taking AIs: Study (0 replies)
  96. Report analyzes global PET SPECT Market (0 replies)
  97. Special Surgery investigators to present future of clinical care at ACR scientific me (0 replies)
  98. Aromatase inhibitors increase side effects in women undergoing breast cancer therapy (0 replies)
  99. Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation (0 replies)
  100. Senior Scientific receives $702,899 for very early cancer detection and treatment (0 replies)
  101. Provectus holds second meeting with Australian TGA to review approval of PV-10 for me (0 replies)
  102. GTx third quarter net loss decreases to $8.6 million (0 replies)
  103. NCIN reports very few lung cancer patients are eligible for surgery (0 replies)
  104. Joint complaints attributed to breast cancer drugs not linked with inflammatory arthr (0 replies)
  105. Smoking increases higher death rate in women with breast cancer (0 replies)
  106. Chemotherapy increases risk in breast cancer patients after surgery (0 replies)
  107. Combination of optical and x-ray imaging may improve diagnostic accuracy of breast sc (0 replies)
  108. Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metast (0 replies)
  109. EpiCept decreases third quarter net loss to $3.2 million (0 replies)
  110. Breast cancer patients prefer silicone implants for postmastectomy reconstructive sur (1 replies)
  111. Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone m (0 replies)
  112. Obesity does not increase breast cancer risk in Mexican-American women: Research (0 replies)
  113. Potential biomarker for measuring progress in breast cancer chemoprevention trials (1 replies)
  114. Soy isoflavone intake decreases risk of invasive breast tumor (0 replies)
  115. CytRx reports $4.4 million net loss for third quarter 2010 (0 replies)
  116. Parascript receives $244,479.25 federal grant under Affordable Care Act (0 replies)
  117. FDA announces reclassification for Full Field Digital Mammography Systems (0 replies)
  118. People with SLE more likely to develop hematologic malignancies (0 replies)
  119. Amgen wins Scrip Best New Drug award for Prolia (0 replies)
  120. Prolonged separation from mother increases risk of breast cancer in young mice (0 replies)
  121. Researchers identify gene linked to melanoma metastasis (0 replies)
  122. Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydne (0 replies)
  123. FDA issues approval letter to Carestream's CR system for mammography (0 replies)
  124. 'Nano-Drug' Hits Brain-Tumor Target: Unique Triggering Device Delivers Antitumor Drug (1 replies)
  125. Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third (0 replies)
  126. AVEO third quarter total collaboration revenues increase to $6.2 million (0 replies)
  127. Researchers uncover regions of brain to produce unique enzyme for estrogen (0 replies)
  128. New cyber-database enables access to information on lymphedema (0 replies)
  129. Breast cancer patients feel post-treatment breast are good in appearance (0 replies)
  130. LVI in breast tissue predicts recurrence of breast cancer in regional lymph nodes (0 replies)
  131. Celsion receives $244,000 grant under QTDP program (0 replies)
  132. OncoMed receives $1.2 million to support therapeutic programs under QTDP program (0 replies)
  133. Celldex third quarter net loss increases to $9.1 million (0 replies)
  134. ArcticDx develops test to determine inherited risk for AMD (0 replies)
  135. NICE to lose its power to ban life saving drugs (0 replies)
  136. Dr Sartori’s contentious alternative therapy: inquest date set (0 replies)
  137. Global Genes Project launches 7,000 Bracelets for Hope campaign to create awareness a (0 replies)
  138. Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards (0 replies)
  139. Two studies evaluating CyberKnife radiosurgery for breast cancer treatment to be pres (0 replies)
  140. Gottlieb Hospital nurse raises $2,000 to fight breast cancer (0 replies)
  141. National Conference to educate breast cancer patients about personal health (0 replies)
  142. Dance for the Cure of Prostate Cancer, national awareness and fundraising campaign la (0 replies)
  143. Accuray to present CyberKnife Robotic Radiosurgery System at ASTRO Meeting (0 replies)
  144. AACR announces launch of new journal, Cancer Discovery (0 replies)
  145. Women with dense breasts and no lobular involution at higher risk for breast cancer (1 replies)
  146. PUMA's Project Pink program raises funds for Women's Cancer Research Center (0 replies)
  147. Merck reports $342 million net income for 2010 third quarter (0 replies)
  148. Research on Rictor protein may provide new molecular target for cancer treatment (0 replies)
  149. Study finds genetic variants that may modify breast cancer risk among women with BRCA (0 replies)
  150. DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million (0 replies)
  151. ImmunoGen first quarter net loss increases to $12.9 million (0 replies)
  152. New oncology training program for registered nurses in Ghana (0 replies)
  153. IsoRay completes Cs-131 brachytherapy seeds feasibility study for breast cancer treat (0 replies)
  154. Researchers unveil evolution in pancreatic tumours (0 replies)
  155. Scientists suggest E-cadherin can function as oncogene in some cancers (0 replies)
  156. Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13 (0 replies)
  157. Study finds green tea does not protect breast cancer (0 replies)
  158. £600 million cancer drug fund for UK cancer patients (0 replies)
  159. Advanced procedure for microsurgical breast reconstruction offered at Baptist Health (0 replies)
  160. Scientists develop new imaging technique that can detect breast cancer treatment resp (0 replies)
  161. ENDOMETRIN Vaginal Insert effective for luteal support in IVF procedures (0 replies)
  162. PSA test helps detect prostate cancer before it spreads (0 replies)
  163. Survey says americans unawareness to lung cancer (0 replies)
  164. New G-DOC repository for biological information (0 replies)
  165. Myriad signs agreement with Abbott for BRACAnalysis (0 replies)
  166. New portable scanner for breast cancer diagnosis (0 replies)
  167. DERMAGENICS Collagen Recovery Cream helps revitalize skin damaged by radiation, chemo (0 replies)
  168. New research focuses on stroma tissue to treat pancreatic cancer (0 replies)
  169. CINJ researcher receives Clinical/Basic Science Research Award (0 replies)
  170. UMC of Göttingen purchases BSD-500 Hyperthermia System (0 replies)
  171. Researchers publish effects of doctor-designed formula against breast cancer (0 replies)
  172. Research Roundup: U.S. life expectancy ratings; Medicare Advantage outlook; Should ad (0 replies)
  173. Experts identify efficient way to increase minority access to colorectal cancer scree (0 replies)
  174. Study finds metabolic syndrome may indicate breast cancer risk in post-menopausal wom (0 replies)
  175. Fred Hutchinson Center offers research-based tip sheets for breast cancer survivors (0 replies)
  176. Valvoline stores raises funds to fight prostate cancer (0 replies)
  177. Primary care-based patient navigation helps health care disparities (0 replies)
  178. Bright Starts announces 2010 Pink Power Mom winners (0 replies)
  179. Task Force: Disparities in breast cancer mortality continue to be high in Chicago (0 replies)
  180. Research could open new way to treat breast cancers (1 replies)
  181. Disparities in breast cancer mortality continues to be high in Chicago: Data (0 replies)
  182. New review outlines Bionovo's platform of estrogen receptor modulators (0 replies)
  183. Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin (0 replies)
  184. Bonati Spine Institute supports National Breast Cancer Awareness (0 replies)
  185. Endocrine Society's Scientific Statement clarifies menopausal hormone therapy risk fo (0 replies)
  186. Colon cancer patients seek less invasive, gentler treatments outside the US (0 replies)
  187. Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months be (0 replies)
  188. Effects of breast cancer do not end after chemotherapy (0 replies)
  189. Hormone therapy associated with increased risk of death from breast cancer (0 replies)
  190. BIOTONE donates $5,000 to Council of Community Clinics to provide diagnostics for bre (0 replies)
  191. Hormone therapy increases breast cancer mortality risk, study finds (0 replies)
  192. Menopausal estrogen replacement therapy speeds growth of ovarian cancer (0 replies)
  193. FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer (0 replies)
  194. A universal cancer treatment for a universal cancer marker (0 replies)
  195. Abbott third quarter worldwide sales increase 11.8% to $8.7 billion (0 replies)
  196. First Edition: October 20, 2010 (0 replies)
  197. More education and attention needed on inflammatory breast cancer (0 replies)
  198. New report focuses inflammatory breast cancer (0 replies)
  199. Study reveals how cells crank up cancer activators (0 replies)
  200. Agendia establishes contract with Humana for coverage of MammaPrint breast cancer rec (0 replies)
  201. Health care reform will lead more people to seek cancer prevention and risk-reduction (0 replies)
  202. Fatalism may prevent Latinas from using cancer screening services (0 replies)
  203. MPI of Biochemistry and GSK collaborate in development of new drugs for type 2 diabet (0 replies)
  204. Medifocus receives two patents to expand IP portfolio (0 replies)
  205. NCCN updates Clinical Practice Guidelines for Breast Cancer (0 replies)
  206. Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cance (0 replies)
  207. AACR's magazine gives detail on immense challenges faced by homeless cancer patients (0 replies)
  208. BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer (0 replies)
  209. Free margin of 2mm from area of invasive breast cancer minimizes residual disease: St (0 replies)
  210. New discovery raises hopes for women with tamoxifen resistance (0 replies)
  211. Celgene acquires Abraxis BioScience (0 replies)
  212. UK Intellectual Property Office allows patent for polymorph of entinostat (0 replies)
  213. Researchers identify genes that predict early menopause (0 replies)
  214. Cancer 'is purely man-made' say scientists...Egyptian mummies (1 replies)
  215. NASA software can help to interpret medical imagery (0 replies)
  216. First Edition: October 15, 2010 (0 replies)
  217. Viral Genetics organizes trials for new therapeutic approach to treat cancer (0 replies)
  218. Scientists discover mechanism of anticancer drug to kill cancer cells (0 replies)
  219. ACS Research Scholar Grant honors Rensselaer researcher for breast cancer study (0 replies)
  220. Think Pink event offers information on breast care to lead healthier life (0 replies)
  221. Tiger Balm sponsors 15th annual Susan G. Komen Miami/Ft. Lauderdale Race for the Cure (0 replies)
  222. Sunshine Biopharma to enter Adva-27a Phase I clinical trial for Multi-Drug Resistant (0 replies)
  223. Risingsun signs consent decree to stop selling unapproved drugs (0 replies)
  224. Researchers seek to end disparities in cancer, stroke care (0 replies)
  225. Humanitas Clinic treats first cancer patient using TrueBeam technology (0 replies)
  226. Canadian Cancer Society announces 'Feast for the Fight' fundraising event (0 replies)
  227. Scientists identify gene that could predict breast cancer patient response to tamoxif (0 replies)
  228. Survey finds most people contribute to breast cancer awareness in past 12 months (0 replies)
  229. Patients with advanced cancer undergo common non-beneficial cancer screening tests (0 replies)
  230. Vegetable consumption decreases risk of estrogen receptor-negative breast cancer in A (0 replies)
  231. US Oncology enrolls 1,000th patient in Phase I clinical trial (0 replies)
  232. Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negati (0 replies)
  233. Cancer patients getting unnecessary tests: Study (0 replies)
  234. Australian women stressed and overweight: Survey (0 replies)
  235. Scientists find role of Rad51 protein in protecting DNA (0 replies)
  236. Engaging in healthy lifestyle can help women with family history control breast cance (0 replies)
  237. AACR announces recipients of Outstanding Investigator Award for Breast Cancer Researc (0 replies)
  238. Racial disparities in breast cancer care persist despite health insurance and socioec (0 replies)
  239. First presentation of anti-HER2 antibody-drug conjugate as first-line therapy for adv (0 replies)
  240. Scripps Research study findings could transform drug development to produce more effe (0 replies)
  241. Healthy lifestyle can reduce breast cancer risk in patients with family history (0 replies)
  242. Mammography, vaccines still raise questions in consumers' minds (0 replies)
  243. Identifying subsets of patients who will respond to subsequent lines of chemotherapy (0 replies)
  244. Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer (0 replies)
  245. Atomic Tattoos launches 'Tats for Tatas' breast cancer awareness fundraising campaign (0 replies)
  246. Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-n (0 replies)
  247. AVEO presents tivozanib Phase 2 study results at ESMO Congress (0 replies)
  248. Researchers to convene for 2010 Advances in Breast Cancer Research Workshop at Univer (0 replies)
  249. Novel hormonal treatments may help ER-negative breast cancer patients: Study (0 replies)
  250. New natural dietary components inhibit breast cancer cells (0 replies)